<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Surgery and Oncology</journal-id><journal-title-group><journal-title xml:lang="en">Surgery and Oncology</journal-title><trans-title-group xml:lang="ru"><trans-title>Хирургия и онкология</trans-title></trans-title-group></journal-title-group><issn publication-format="electronic">2949-5857</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">41</article-id><article-id pub-id-type="doi">10.17650/2220-3478-2013-0-1-11-18</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>IN FOCUS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>В ЦЕНТРЕ ВНИМАНИЯ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">NEOADJUVANT THERMOCHEMORADIOTHERAPY USING INTRARECTAL 5-FLUORURACIL IN COMBINED TREATMENT OF RECTAL CANCER</article-title><trans-title-group xml:lang="ru"><trans-title>НЕОАДЪЮВАНТНАЯ ТЕРМОХИМИОЛУЧЕВАЯ ТЕРАПИЯ С ВНУТРИРЕКТАЛЬНЫМ ВВЕДЕНИЕМ 5-ФТОРУРАЦИЛА В КОМПЛЕКСНОМ ЛЕЧЕНИИ БОЛЬНЫХ РАКОМ ПРЯМОЙ КИШКИ</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Barsukov</surname><given-names>Yu. A.</given-names></name><name xml:lang="ru"><surname>Барсуков</surname><given-names>Ю. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>barsukov@oncoproct.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Tkachev</surname><given-names>S. I.</given-names></name><name xml:lang="ru"><surname>Ткачев</surname><given-names>С. И.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>barsukov@oncoproct.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Oltarzhevskaya</surname><given-names>N. D.</given-names></name><name xml:lang="ru"><surname>Олтаржевская</surname><given-names>Н. Д.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>barsukov@oncoproct.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kuzmichev</surname><given-names>D. V.</given-names></name><name xml:lang="ru"><surname>Кузьмичев</surname><given-names>Д. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>barsukov@oncoproct.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Mamedli</surname><given-names>Z. Z.</given-names></name><name xml:lang="ru"><surname>Мамедли</surname><given-names>З. З.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>barsukov@oncoproct.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Pavlova</surname><given-names>A. M.</given-names></name><name xml:lang="ru"><surname>Павлова</surname><given-names>А. М.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>barsukov@oncoproct.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Malikhov</surname><given-names>A. G.</given-names></name><name xml:lang="ru"><surname>Малихов</surname><given-names>А. Г.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>barsukov@oncoproct.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kholyavka</surname><given-names>E. N.</given-names></name><name xml:lang="ru"><surname>Холявка</surname><given-names>Е. Н.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>barsukov@oncoproct.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow</institution></aff><aff><institution xml:lang="ru">ФГБУ «Российский онкологический центр им. Н.Н. Блохина» РАМН, Москва</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2013-02-28" publication-format="electronic"><day>28</day><month>02</month><year>2013</year></pub-date><volume>2</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>11</fpage><lpage>18</lpage><history><date date-type="received" iso-8601-date="2015-02-28"><day>28</day><month>02</month><year>2015</year></date><date date-type="accepted" iso-8601-date="2015-02-28"><day>28</day><month>02</month><year>2015</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2013, ABV-press</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2013, АБВ-пресс</copyright-statement><copyright-year>2013</copyright-year><copyright-holder xml:lang="en">ABV-press</copyright-holder><copyright-holder xml:lang="ru">АБВ-пресс</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://onco-surgery.info/jour/about/editorialPolicies</ali:license_ref></license></permissions><self-uri xlink:href="https://onco-surgery.info/jour/article/view/41">https://onco-surgery.info/jour/article/view/41</self-uri><abstract xml:lang="en"><p>Safety and efficacy of intrarectal 5-fluoruracil in combined treatment of localized rectal cancer was investigated in this article. Our data supports safety, economical efficacy and simplicity of use of this method. It improves sphincter preservation rate in patients with distal rectal cancer, does not increase surgical mortality and morbidity, leads to high tumor regression rate, improves local control and decreases distant failure rate.</p></abstract><trans-abstract xml:lang="ru"><p>В статье представлены результаты изучения эффективности и переносимости созданного нового варианта комплексного лечения больных первично-операбельным раком прямой кишки (РПК) с использованием интраректального введения 5-фторурацила. Полученные данные позволяют говорить о том, что новый созданный способ дешев и прост в использовании, обладает приемлемым профилем токсичности, большинству больных РПК дистальной локализации позволяет провести сфинктеросохраняющие операции, не приводит к повышению числа осложнений, связанных с оперативным вмешательством, способствует развитию высоких показателей  лечебного патоморфоза, обеспечивает адекватный локальный контроль заболевания и позволяет достоверно снизить частоту возникновения отдаленных метастазов.</p></trans-abstract><kwd-group xml:lang="en"><kwd>rectal cancer</kwd><kwd>combined treatment</kwd><kwd>5-fluoruracil</kwd><kwd>capecitabine</kwd><kwd>tegafur</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>рак прямой кишки</kwd><kwd>комплексное лечения</kwd><kwd>5-фторурацил</kwd><kwd>капецитабин</kwd><kwd>тегафур</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">1. Glimelius B. Chemoradiotherapy for rectal cancer – is there an optimal combination? Ann Oncol 2001 Aug;12(8):1039–45.</mixed-citation><mixed-citation xml:lang="ru">Glimelius B. Chemoradiotherapy for rectal cancer – is there an optimal combination? Ann Oncol 2001 Aug;12(8):1039–45.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">2. Grann A., Minsky B.D., Cohen A.M. Preliminary results of preoperative 5-fluorouracil, low dose leucovorin, and concurrent radiation therapy for resectable T3 rectal cancer. Dis Colon Rectum 1997;40(5):515–22.</mixed-citation><mixed-citation xml:lang="ru">Grann A., Minsky B.D., Cohen A.M. Preliminary results of preoperative 5-fluorouracil, low dose leucovorin, and concurrent radiation therapy for resectable T3 rectal cancer. Dis Colon Rectum 1997;40(5):515–22.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">3. Ichikawa D., Yamaguchi T., Yoshioka Y. et al. Prognostic evaluation of preoperative combined treatment for advanced cancer in the lower rectum with radiation, intraluminal hyperthermia, and 5-fluorouracil suppository. Am J Surg 1996 Mar;171(3):346–50.</mixed-citation><mixed-citation xml:lang="ru">Ichikawa D., Yamaguchi T., Yoshioka Y. et al. Prognostic evaluation of preoperative combined treatment for advanced cancer in the lower rectum with radiation, intraluminal hyperthermia, and 5-fluorouracil suppository. Am J Surg 1996 Mar;171(3):346–50.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">4. Ngan S.Y., Michael M., Mackay J. et al. A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer. Br J Cancer 2004;91(6):1019–24.</mixed-citation><mixed-citation xml:lang="ru">Ngan S.Y., Michael M., Mackay J. et al. A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer. Br J Cancer 2004;91(6):1019–24.</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">5. O’Neil B.H., Tepper J.E. Current options for the management of rectal cancer. Curr Treat Options Oncol 2007;8(5):331–8.</mixed-citation><mixed-citation xml:lang="ru">O’Neil B.H., Tepper J.E. Current options for the management of rectal cancer. Curr Treat Options Oncol 2007;8(5):331–8.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">6. Барсуков Ю.А. и др. Комбинированное и комплексное лечение больных раком прямой кишки. М., 2011. 96 с.</mixed-citation><mixed-citation xml:lang="ru">Барсуков Ю.А. и др. Комбинированное и комплексное лечение больных раком прямой кишки. М., 2011. 96 с.</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">7. NCCN: Clinical Practice Guidelines in Oncology. Rectal Cancer, v.2. 4.2013.</mixed-citation><mixed-citation xml:lang="ru">NCCN: Clinical Practice Guidelines in Oncology. Rectal Cancer, v.2. 4.2013.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">8. Glimelius B., Oliveira J., and ESMO Guidelines Working Group. Rectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20 Suppl 4:54–6.</mixed-citation><mixed-citation xml:lang="ru">Glimelius B., Oliveira J., and ESMO Guidelines Working Group. Rectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20 Suppl 4:54–6.</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">9. Schüller J., Cassidy J., Dumont E. et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000;45(4):291–7.</mixed-citation><mixed-citation xml:lang="ru">Schüller J., Cassidy J., Dumont E. et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000;45(4):291–7.</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">10. Hoff P.M., Ansari R., Batist G. et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first line treatment in 605 patients with metastatic сolorectal cancer: results of a randomized phase III study. J Clin Oncol 2001;19:2282–92.</mixed-citation><mixed-citation xml:lang="ru">Hoff P.M., Ansari R., Batist G. et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first line treatment in 605 patients with metastatic сolorectal cancer: results of a randomized phase III study. J Clin Oncol 2001;19:2282–92.</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">11. De Paoli A., Chiara S., Luppi G. et al. Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer: a multicentric phase II study. Ann Oncol 2006;17(2):246–51.</mixed-citation><mixed-citation xml:lang="ru">De Paoli A., Chiara S., Luppi G. et al. Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer: a multicentric phase II study. Ann Oncol 2006;17(2):246–51.</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">12. Dunst J., Reese T., Sutter T. et al. Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. J Clin Oncol 200;20(19):3983–91.</mixed-citation><mixed-citation xml:lang="ru">Dunst J., Reese T., Sutter T. et al. Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. J Clin Oncol 200;20(19):3983–91.</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">13. Пелевина И.И., Воронина С.С., Каракуло в Р.К. и др. Метронидазол, основные экспериментальные результаты, перспективы для клиники. Мед радиол 1984;2:10–20.</mixed-citation><mixed-citation xml:lang="ru">Пелевина И.И., Воронина С.С., Каракуло в Р.К. и др. Метронидазол, основные экспериментальные результаты, перспективы для клиники. Мед радиол 1984;2:10–20.</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">14. Холин В.В. Радиобиологические основы лучевой терапии злокачественных опухолей. Л.:Медицина, 1979. 223 с.</mixed-citation><mixed-citation xml:lang="ru">Холин В.В. Радиобиологические основы лучевой терапии злокачественных опухолей. Л.:Медицина, 1979. 223 с.</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">15. Takahashi T., Horie H., Kojima O., Itoh M. Preoperative combined treatment with radiation, intraluminal hyperthermia, and 5-fluorouracil suppositories for patients with rectal cancer. Surg Today 1993;23(12):1043–8.</mixed-citation><mixed-citation xml:lang="ru">Takahashi T., Horie H., Kojima O., Itoh M. Preoperative combined treatment with radiation, intraluminal hyperthermia, and 5-fluorouracil suppositories for patients with rectal cancer. Surg Today 1993;23(12):1043–8.</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">16. National Cancer Institute, Common Terminology Criteria for Adverse Events (CTCAE) v3.0.</mixed-citation><mixed-citation xml:lang="ru">National Cancer Institute, Common Terminology Criteria for Adverse Events (CTCAE) v3.0.</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">17. Лавникова Г.А. Некоторые закономерности лучевого патоморфоза опухолей человека и их практическое использование. Вестник АМН СССР 1976;6:13–9.</mixed-citation><mixed-citation xml:lang="ru">Лавникова Г.А. Некоторые закономерности лучевого патоморфоза опухолей человека и их практическое использование. Вестник АМН СССР 1976;6:13–9.</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">18. Dworak O., Keilholz L., Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 1997;12:19–23.</mixed-citation><mixed-citation xml:lang="ru">Dworak O., Keilholz L., Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 1997;12:19–23.</mixed-citation></citation-alternatives></ref></ref-list></back></article>
